Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Sep 09, 2025
Episode
316
Soundcloud
Share
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference.
Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR-positive, previously treated NSCLC.
Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR-positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.
Guest
Stephen Liu
MD
Chief of Hematology and Oncology
Georgetown University
Wenfeng Fang
MD, PhD
Medical Oncologist
Sun Yat-sen University Cancer Center
Biagio Ricciuti
MD, PhD
Thoracic Medical Oncologist and Data Scientist
Dana-Farber Cancer Institute
Faculty, Harvard Medical School
Susan Scott
MD
Medical Oncologist, Assistant Professor of Oncology
Johns Hopkins School of Medicine
